CLDN Stock UPDATES Celladon Corp (CLDN) 10.31 10/21/2014 22:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celladon Corp (CLDN) 10.31 $CLDN

Celadon Group Announces Executive Team Changes
PR Newswire - Tue Oct 21, 3:57PM CDT
Celadon Group, Inc. (NYSE: CGI) today announced changes to its executive team. The changes are effective immediately.
CLDN: 10.31 (+0.49), CGI: 19.57 (+0.95)

Celadon Group Announces Dates for Earnings Release and Conference Call and for Upcoming Investor Conferences
PR Newswire - Fri Oct 03, 9:19AM CDT
Celadon Group Inc. (NYSE: CGI) will release its fiscal 2015 first quarter results on Wednesday, October 29 after the close of the market. A conference call to discuss the first quarter results will be held Thursday, October 30 at 11:00 a.m. Eastern Time.
CLDN: 10.31 (+0.49), CGI: 19.57 (+0.95)

Micro-Cap Biotechs: The Next Billion Dollar Drug Is Coming From...?
OptionVol - Thu Oct 02, 5:33PM CDT
This visualization is provided by: Capital Market Laboratories (join the queue: free trial) Micro Cap Bio-techs: Who's Investing in R&D? Note that the firms above the blue line I've drawn in are pouring in at least $0.60 into researc...
LOXO: 11.30 (+0.13), DNDN: 1.10 (-0.03), VNDA: 10.19 (-0.37), OSIR: 13.01 (+0.09), CLDN: 10.31 (+0.49), GALE: 1.92 (+0.09), CTIC: 2.37 (-0.02), OTIC: 23.71 (+0.97)

Celladon to Present at the 2014 Stem Cell Meeting on the Mesa
GlobeNewswire - Wed Oct 01, 3:15PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer, will present a corporate overview at the 4th Annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, CA.
CLDN: 10.31 (+0.49)

Celladon Corporation Appoints Scott Garrett Vice President, Commercial Planning
GlobeNewswire - Mon Sep 22, 7:07AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced it has appointed Scott Garrett as Vice President, Commercial Planning, a newly created position.
JNJ: 100.36 (+1.16), GILD: 106.67 (+4.46), CLDN: 10.31 (+0.49)

Global Chronic Heart Failure Therapeutics Pipeline Review 2014 - 21 Companies & 31 Drug Profiles
M2 - Thu Sep 11, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wx7flm/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Amgen Inc. - Sanofi - Novartis AG - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Pfizer Inc. - Bayer AG - Celladon Corporation - Mesoblast Limited - Palatin Technologies, Inc. - AnGes MG, Inc. - MetrioPharm AG - Cyano Biotech GmbH - NormOxys, Inc. - Cardioxyl Pharmaceuticals, Inc. - PhaseBio Pharmaceuticals, Inc. - miRagen Therapeutics, Inc. - Fibrotech Therapeutics Pty. Ltd. - Otsuka Holdings Co., Ltd. - Zensun (Shanghai) Sci & Tech Co., Ltd. Drug Profiles - Neucardin - rivaroxaban - (sacubitril valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - ivabradine - PL-3994 - omecamtiv mecarbil - Mydicar - CXL-1020 - serelaxin (recombinant) - tolvaptan - finerenone - ivabradine - F-373280 - Stem Cell Therapy for Cardiovascular Diseases - cenderitide - beperminogene perplasmid - OXY-111A - Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - MGN-9103 - BR-5489 - FT-011 - PB-1046 - Cell Therapy for Chronic Heart Failure - SAR-296968 - RNAi Gene Therapy to Inhibit STIM1 for Cardiovascular Diseases - Peptides Inhibiting ACE for Cardiovascular and Metabolic Disorders - Vestiras For more information visit http://www.researchandmarkets.com/research/wx...onic_heart
PFE: 28.28 (+0.35), PTN: 0.69 (-0.01), CLDN: 10.31 (+0.49), AMGN: 144.09 (+6.58), NVS: 88.61 (+0.71)

Nasdaq stocks posting largest percentage increases
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
LOXO: 11.30 (+0.13), ACET: 19.87 (+0.37), MAGS: 4.02 (-0.07), CLDN: 10.31 (+0.49)

Why You Shouldn't Bet Against Celladon Corporation (CLDN) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 7:57AM CDT
Celladon is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
CLDN: 10.31 (+0.49)

Celladon Corp. (CLDN) Jumps: Stock Adds 11.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 7:51AM CDT
Celladon Corporation (CLDN) was a big mover last session, as its shares rose over 11% on the day.
CBPO: 52.11 (+0.11), CBM: 17.88 (+0.14), GILD: 106.67 (+4.46), CLDN: 10.31 (+0.49)

5 Stocks Moving on Unusual Volume
at The Street - Tue Aug 19, 6:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
DRTX: 24.09 (+0.41), MVNR: 11.03 (+0.48), WBMD: 38.34 (+0.24), CRTO: 30.21 (+0.42), CLDN: 10.31 (+0.49)

Celladon Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Mon Aug 18, 3:05PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced the closing of its underwritten public offering of 4,600,000 shares of its common stock at $9.50 per share, including 600,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, resulting in gross proceeds from the offering of $43.7 million before deducting underwriting discounts and commissions and other offering expenses payable by Celladon.
CLDN: 10.31 (+0.49)

Nasdaq stocks posting largest volume increases
AP - Thu Aug 14, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
RRGB: 51.08 (-0.24), TLMR: 13.93 (+0.43), BTUI: 3.20 (+0.41), LINTB: 30.07 (+1.98), CLDN: 10.31 (+0.49), BRID: 8.50 (+0.01), LINTA: 29.92 (+1.79), BYBK: 4.55 (-0.07), ARTW: 5.29 (-0.11), NDQ.TO: 12.61 (+0.54), NDLS: 22.87 (+0.21), FBMS: 14.55 (+0.15), INPH: 3.02 (+0.34), ONVI: 4.34 (+0.19), NVDQ: 11.20 (+0.50)

Celladon (CLDN) Falls: Stock Goes Down 6.2% - Tale of the Tape
Zacks Research Stuff - Zacks Investment Research - Wed Aug 13, 7:30AM CDT
Celladon stock fell over 6% last trading session, continuing its recent downtrend
HSKA: 12.16 (-0.24), CBM: 17.88 (+0.14), GILD: 106.67 (+4.46), CLDN: 10.31 (+0.49)

Celladon Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Tue Aug 12, 5:06PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at $9.50 per share. The gross proceeds to Celladon from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Celladon, are expected to be approximately $38.0 million. Celladon has also granted the underwriters a 30-day option to purchase up to an aggregate of 600,000 additional shares of common stock. The offering is scheduled to close on August 18, 2014, subject to customary closing conditions.
CLDN: 10.31 (+0.49)

Celladon Announces Initiation of Clinical Trial to Investigate MYDICAR in Patients With Heart Failure and a Left Ventricular Assist Device (LVAD)
GlobeNewswire - Mon Aug 11, 3:00AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that the first patient has been dosed in a clinical trial titled "Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients with Heart Failure and a Left Ventricular Assist Device (LVAD)," which is designed to assess the potential utility of MYDICAR in advanced heart failure patients whose hearts are being supported by LVADs. This trial is partially funded by the British Heart Foundation and sponsored by Imperial College London.
CLDN: 10.31 (+0.49)

Celladon Reports Second Quarter 2014 Financial Results and Recent Highlights
GlobeNewswire - Thu Aug 07, 5:31AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced financial results for the quarter ended June 30, 2014 and recent highlights.
CLDN: 10.31 (+0.49)

Celladon Announces Commencement of Public Offering of Common Stock
GlobeNewswire - Thu Aug 07, 5:30AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that it is offering to sell 4,000,000 shares of its common stock in an underwritten public offering. In connection with this offering, Celladon will also grant to the underwriters a 30-day option to purchase up to an aggregate of 600,000 additional shares of common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
CLDN: 10.31 (+0.49)

Celadon Group Reports June Quarter And Full Fiscal Year Results And Declares Dividend
PR Newswire - Wed Aug 06, 4:06PM CDT
Celadon Group Inc. (NYSE: CGI) today reported its financial and operating results for the three months and fiscal year ended June 30, 2014, the fourth fiscal quarter of the Company's fiscal year ending June 30, 2014.
CLDN: 10.31 (+0.49), CGI: 19.57 (+0.95)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 113

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 34

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 86

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Cargo Drones to Skyrocket with $9.14B Value by 2031

Updated Category News Views 16

Riding the Drone Wave I tell you what, folks, the whole business of cargo drones is getting frickin' interesting. These flying gizmos, once dismissed as science fiction, are now barging their way into logistics discussions like an uninvited guest who's too worthwhile to ignore. MarketsandMarkets™ reckons this market's about to smash through the $9 billion ceiling by...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 427

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 372

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 42

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 103

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options

Updated Category News Views 55

Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...

Continue Reading

Top 5 Most Recently Viewed Articles

Insigneo Welcomes Esteban Diaz to Enhance Wealth Management

Updated Category News Views 159

Insigneo Strengthens Its Wealth Management Team Insigneo, a prominent name in wealth management, proudly announces the addition of Esteban Diaz as Senior Vice President. This significant recruitment is part of the firm’s ongoing commitment to enhancing its network, particularly in serving high-net-worth clients in the Latin American region. About Esteban Diaz's...

Continue Reading
Exploring RBC Bearings: A Five-Year Investment Journey

Updated Category News Views 172

RBC Bearings: A Strong Investment Over Time RBC Bearings has proven to be a formidable player in the market, showcasing impressive performance over the last five years. With an average annual return of 18.74%, any investment made during this period would have reaped considerable rewards. The Growth of a $1000 Investment Imagine if you had decided to invest $1000 in RBC...

Continue Reading
ANI Pharmaceuticals Enhances Ophthalmology Strategy with Experts

Updated Category News Views 227

ANI Pharmaceuticals Launches FutureVision Advisory Council In a strategic move to bolster its ophthalmology and retina franchise, ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has established the FutureVision Advisory Council. This dedicated council aims to guide the ongoing innovations within ANI's Rare Disease portfolio, focusing particularly on ophthalmological care....

Continue Reading
Unlocking Financial Freedom: The CESUR Mining Game Changer

Updated Category News Views 99

Understanding CESUR Mining and Its Impact CESUR Mining is quickly becoming a significant player in the world of cryptocurrency. This innovative platform enables users to tap into the potential of cloud mining, allowing them to earn passive income without the need for technical knowledge or constant monitoring. Established with the vision to simplify the mining process,...

Continue Reading
Understanding Nvidia's Role in the S&P 500 Market Dynamics

Updated Category News Views 204

Nvidia's Influence on the S&P 500 Market The stock market can be quite a wild ride, with swings that can astonish even the most experienced investors. Recently, stocks started off relatively flat but soon encountered volatility, leading to a significant rally largely fueled by news surrounding Nvidia. This surge prompts important questions about how the S&P 500 will...

Continue Reading